Subcutaneous Immunoglobulin Replacement Following CD19-Specific Chimeric Antigen Receptor-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia

Background: Chimeric antigen receptor-modified T cell therapy targeting CD19 (CART-19) has recently been approved for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Successful CART-19 therapy is expected to result in prolonged B cell aplasia and agammaglobulinemia. As such, immunoglobulin replacement is essential for the prevention of serious bacterial infections. Several studies in patients with primary humoral...